Fig. 3From: Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapyKaplan-Meier analysis on event-free survival (EFS) in complete remission (CR) patients. A EFS in all 13 CR patients. B EFS in 11 patients who received allogeneic hematopoietic cell transplantation following hCD19 CAR-TBack to article page